The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1363
Duloxetine (Cymbalta) for Chronic Musculoskeletal Pain
The full article is available to subscribers Subscriber Login   

Previously approved by the FDA for treatment of depression, general anxiety disorder, diabetic peripheral neuropathic pain and fibromyalgia,1,2 duloxetine (Cymbalta – Lilly) has now also been approved for treatment of chronic musculoskeletal pain.

MECHANISM OF ACTION — Duloxetine is a selective serotonin and norepinephrine reuptake inhibitor (SNRI). Its mechanism of action in reducing pain is unknown.

CLINICAL STUDIES — Chronic Low Back Pain – Three double-blind, randomized, 3-month trials of duloxetine in a total of >1000 patients with chronic (≥6 months) low back pain have been published and are summarized in the package insert.3-5 All were conducted by employees of the manufacturer. Two of the three trials found duloxetine more effective than placebo in reducing pain, as measured by Brief Pain ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Duloxetine (Cymbalta) for Chronic Musculoskeletal Pain
Article code: 1363a
 Electronic, downloadable article - $25